ASTC vs SONM
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ASTC exhibits severe financial distress, as evidenced by a Piotroski F-Score of 1/9 (indicating weak financial health) and a lack of Altman Z-Score data, which raises bankruptcy risk concerns. The company reports a negative operating margin of -2,635.81%, a -43.3% YoY revenue decline, and a -244.4% YoY EPS growth, signaling deteriorating fundamentals. Despite a low Price/Book of 0.30, the stock trades at a premium to its intrinsic value due to speculative momentum, with no dividend, no analyst coverage, and bearish insider activity. The 5-year price decline of 96% underscores deep investor skepticism and structural challenges.
The company exhibits extreme financial distress, highlighted by a Piotroski F-Score of 0/9, indicating a total lack of fundamental health. With a Quick Ratio of 0.03 and a negative Price-to-Book ratio of -4.35, the firm is facing a severe liquidity crisis and possesses negative shareholders' equity. Catastrophic Q/Q revenue growth of -394.48% and a 5-year price decline of 99.7% suggest a business in terminal decline. The lack of an Altman Z-Score calculation is likely due to the absence of positive working capital or equity, further signaling insolvency risk.
Compare Another Pair
Related Comparisons
ASTC vs SONM: Head-to-Head Comparison
This page compares Astrotech Corporation (ASTC) and DNA X, Inc. (SONM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.